American Academy of Ophthalmology

Woolfson Eye Institute Opening an Office in Marietta, Georgia

Retrieved on: 
Saturday, November 19, 2022
Indian Medical Association, American Society of Cataract and Refractive Surgery, Dyak, American Academy of Ophthalmology, American Medical Association, DO, WEI, Society, Retina, DRS, Permit, Macular degeneration, Intraocular lens, Glaucoma, Contact lens, OD, Sprayberry High School, Diabetic retinopathy, Patient, ICL, Wells Fargo, Outpatient surgery, Cataract, Keratoconus, Eyelid, Surgeon, American Academy, International Society, Refractive surgery, Hospital, Veterinary medicine, MD, LASIK, Ophthalmology

MARIETTA, Ga., Nov. 19, 2022 /PRNewswire/ -- Woolfson Eye Institute will open a new Marietta office in November 2022.

Key Points: 
  • MARIETTA, Ga., Nov. 19, 2022 /PRNewswire/ -- Woolfson Eye Institute will open a new Marietta office in November 2022.
  • The practice ultimately evolved into a referral destination for patients in need of other types of eye care, as well.
  • About LASIK eye surgery and Jonathan Woolfson, MD
    Jonathan Woolfson, MD, a LASIK pioneer, and his team of surgeons have performed over 100,000 LASIK procedures.
  • Woolfson Eye Institute, headquartered in Atlanta, GA, is the Southeast's leading provider for LASIK, oculoplastics, cataract surgery, retina, glaucoma and other eye disorders.

Verana Health Developing Qdata MS, a Real-World Data, Curated Neurology Research Module for Multiple Sclerosis

Retrieved on: 
Wednesday, November 16, 2022
Quality of life, SAN, Doctor of Philosophy, American Academy of Neurology, HCP, EHR, National Multiple Sclerosis Society, Classification, MD, American Academy of Ophthalmology, Health, Woman, Population, Parkinson's disease, Solution, MS, RWD, Physician, Data management, Man, Medicine, Spinal cord, Data, Phenotype, ICDS, Multiple sclerosis, EDSS, Intelligence, Research, NMOSD, Patient, Stanford University, CEO, RWE, American Urological Association, Central nervous system, HCPS, Immune system, Brain, CNS, Diagnosis, American Academy, Disease, SMA, Pharmaceutical industry, Medical imaging, Ophthalmology, Neurology

SAN FRANCISCO, Nov. 16, 2022 /PRNewswire/ -- Verana Health a digital health company elevating quality in real-world data (RWD)today announced it is developing Qdata MS , a Neurology Qdata module that will be used to help advance clinical research and develop therapeutic strategies for treating patients with multiple sclerosis (MS).

Key Points: 
  • SAN FRANCISCO, Nov. 16, 2022 /PRNewswire/ -- Verana Health a digital health company elevating quality in real-world data (RWD)today announced it is developing Qdata MS , a Neurology Qdata module that will be used to help advance clinical research and develop therapeutic strategies for treating patients with multiple sclerosis (MS).
  • The Axon Registry, managed by Verana Health's VeraQ population health data engine, is one of the largestand growingreal-world clinical data registries for neurology.
  • As the Qdata MS module evolves through development, it is estimated to include de-identified, curated RWD from about 30,000 patients diagnosed with MS, one of the largest longitudinal multiple sclerosis datasets for research use.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.

Luminopia, Inc. Announces Oversubscribed Seed Extension Financing Round

Retrieved on: 
Friday, November 11, 2022
Children, Clinical Trials, Health Technology, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Optical, Dai, Visual acuity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, FDA, Ageing, Amblyopia, Eye, Food, Anisometropia, Astigmatism, VR, Parent, Atropine, De novo, Neuro, Technology, Severe cognitive impairment, Strabismus, Silicon, Partner, Patient, Cataract, Safety, Silicon Valley Bank, New Device, Far-sightedness, Biotechnology, Hospital, Entrepreneurship, American Academy of Ophthalmology, Therapy, Virtual reality, HMDS, Myopia, HMD, Physician, Industry, Compliance, Pharmaceutical industry, MD, Ophthalmology

Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.

Key Points: 
  • Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.
  • ShangBay Capital led the round, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strategy, as well as support from existing investors.
  • With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopias Board of Directors.
  • Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy.

Iridex Announces Record Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Retina, Marketing, Investment, U.S. Securities and Exchange Commission, OUS, Nasdaq, American Academy of Ophthalmology, Adoption, DME, Securities Act of 1933, Diabetic retinopathy, Fruit, American Academy, Company, G6, United, Glaucoma, Pascal, Awareness, Growth, CEO, Security (finance), Energy Independence and Security Act of 2007, IRIX, FDA, Medical device, Cryptocurrency, Pharmaceutical industry, Video game, Ophthalmology

MOUNTAIN VIEW, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022.
  • We look forward to our first shipments this fourth quarter, and sharing more information in the weeks ahead.
  • Total product revenue from the Cyclo G6 glaucoma product family was $3.5 million, 10% higher than the third quarter of 2021.
  • Other revenue, which includes royalties, services, and other legacy products, increased 4% to $2.4 million in the third quarter of 2022 compared to the prior year.

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
Molecule, Bausch & Lomb, Choroid, GLOBE, Private Securities Litigation Reform Act, Investor, Periodic Report of the United States of America to the United Nations Committee Against Torture, SCS, Pharming, Annual general meeting, Safety, Webcast, American Academy of Ophthalmology, Society, Eye, ASRS, CLS, SEC, Annual report, NASDAQ, American Academy, OIS, AMD, U.S. Securities and Exchange Commission, Axitinib, Retina, Company, Government, Research, Conference, Awareness, Patient, ET, AAO, OASIS, COVID-19, Conference call, Pharmaceutical industry, Medical device, Video game, Clearside

ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Clearsides license and other revenue for the third quarter of 2022 was $0.3 million, compared to $3.1 million for the third quarter of 2021.
  • Research and development expenses for the third quarter of 2022 were $4.6 million, compared to $5.1 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $2.4 million, compared to $2.8 million for the third quarter of 2021.

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Retrieved on: 
Thursday, November 10, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Oncology, Quality of life, CM, Review, Private Securities Litigation Reform Act, Adult, Annual report, American Academy of Ophthalmology, VDC, Risk, Intention, American Academy, Arm, Efficiency, Compte rendu, Cancer, SEC, NASDAQ, Patient, NMIBC, Safety, Aura, U.S. Securities and Exchange Commission, Goal, Probability, Immune system, Acral lentiginous melanoma, Radiation, COVID-19, Pharmaceutical industry, Ophthalmology

After presenting positive interim data at the American Academy of Ophthalmology from its ongoing Phase 2 trial, Aura has aligned with regulatory agencies and finalized the design of the global Phase 3 trial.

Key Points: 
  • After presenting positive interim data at the American Academy of Ophthalmology from its ongoing Phase 2 trial, Aura has aligned with regulatory agencies and finalized the design of the global Phase 3 trial.
  • The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
  • We are pleased to have aligned with regulatory agencies on the overall Phase 3 trial design, including the primary and key secondary endpoints.
  • Aura is planning to enroll approximately 75 adult patients with eary-stage CM, including patients with indeterminte lesions and small choroidal melanoma.

Verana Health to Present Findings of Diabetic Retinopathy Study Using American Academy of Ophthalmology IRIS® Registry Data at AMIA Annual Symposium

Retrieved on: 
Monday, November 7, 2022
MNAR, Severe cognitive impairment, ICD, Research, Academy, Washington Hilton, HCPS, American Medical Informatics Association, Diabetic retinopathy, CDC, Varnaq, American Academy, Data curation, Vivek Borkar, MAR, Poster, Quality of life, American Urological Association, Data management, Electronic health record, Center, American Academy of Neurology, Medicine, Health information management, Health, IRIS, Mechanism, Area studies, MCAR, Columbia Hall, Report of the 1st Annual Symposium on Relaxed Improvisation, American Academy of Ophthalmology, Natural language processing, PS02, Korea Disease Control and Prevention Agency, HCP, Missing data, Diabetes, Disease, Millennium, Patient, AMIA, Solution, Pharmaceutical industry, Medical device, D.C, Ophthalmology, MD

The title of the study described in the poster is " Understanding Mechanisms of Missingness for Unspecified Diabetic Retinopathy Disease Severity in the Electronic Health Record: An IRIS Registry Analysis."

Key Points: 
  • The title of the study described in the poster is " Understanding Mechanisms of Missingness for Unspecified Diabetic Retinopathy Disease Severity in the Electronic Health Record: An IRIS Registry Analysis."
  • Established in 2014, the IRIS Registry is one of the largest specialty society clinical data registries in all of medicine.
  • The results of this study suggest that diabetic retinopathy disease severity is likely MNAR in the electronic health record.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.

Verana Health to Present Findings of Studies Using American Academy of Ophthalmology IRIS® Registry Data to Advance Insights into Real World Outcomes in Treating AMD

Retrieved on: 
Wednesday, November 2, 2022
Millennium, American Academy, MD, NAMD, Blood, Retinal degeneration (rhodopsin mutation), Durability, Doctor of Philosophy, Brolucizumab, Geographic atrophy, Machine Intelligence Research Institute, HCPS, American Academy of Ophthalmology, Research, AMD, Patient, RWD, Comparison, VEGF, Department, Varnaq, Data management, American Academy of Neurology, Academy, Rush University Medical Center, CATT, HCP, Medicine, Novartis, FDA, American Urological Association, IgG4-related ophthalmic disease, Clinical trial, Poster, Severe cognitive impairment, SAN, Quality of life, Solution, Pharmaceutical industry, Medical imaging, Ophthalmology

SAN FRANCISCO, Nov. 2, 2022 /PRNewswire/ -- During The Retina Society's 55th Annual Scientific Meeting Nov. 2 to 5, Verana Health®—a digital health company elevating quality in real-world data—will present findings on two separate studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight).

Key Points: 
  • treatment arms of the CATT trial using de-identified IRIS Registry data from a real-world population to compare treatment outcomes at one year to the monthly treatment arms of the CATT using patient-level clinical trial data.
  • Established in 2014, the IRIS Registry is one of the largest specialty society clinical data registries in all of medicine.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

Prevent Blindness Revamps, Expands its "Living Well With Low Vision" Online Resource

Retrieved on: 
Wednesday, November 2, 2022
People, Well, American Academy, The Vision Council, Severe cognitive impairment, CEO, Visual impairment, Cataract, YouTube, American Academy of Ophthalmology, Research, Glaucoma, AMD, Risk, Research to Prevent Blindness, ABC, Website, Safety, Social isolation, Anxiety, Health care, Patient, Caregiver, Conditional sentence, Health professional, Health insurance, Pharmaceutical industry, Telescopic sight, Management, Facebook, Ophthalmology

CHICAGO, Nov. 2, 2022 /PRNewswire-PRWeb/ -- To provide comprehensive information and a user-friendly experience to the millions of low vision patients, their caregivers, and healthcare professionals, Prevent Blindness, the nation's leading eye health and safety nonprofit organization, is launching the newly redesigned resource, "Living Well With Low Vision."

Key Points: 
  • Although low vision can occur at any age, it is primarily associated with older populations.
  • To help users navigate the new site, Prevent Blindness is hosting a free webinar, " Introducing a New Low Vision Resource from Prevent Blindness, " to be held on Nov. 16, 2022, at 6 p.m.
  • Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight.
  • Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America.

Medicare cuts harming seniors' access to surgical care set to take effect in less than two months

Retrieved on: 
Tuesday, November 1, 2022
Surgeon, FACS, Neurology, American Academy of Ophthalmology, Congress, FASA, Breast cancer, MBA, Politics, Refractive surgery, Centers for Medicare & Medicaid Services, Advocacy, American Society of Cataract and Refractive Surgery, Patient, Ophthalmology, Risk, Physician, CMS, American Society of Anesthesiologists, Statute, American Society of Breast Surgeons, Medicare, Anesthesiology, Woman, Investor, Cataract, Health policy, Multimedia, ACS, Society for Vascular Surgery, Quality of life, Center, Society, Association, Global Initiative for Emergency and Essential Surgical Care, Solution, Pharmaceutical industry, Health insurance, MD

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- The 2023 Medicare Physician Fee Schedule final rule released today by the Centers for Medicare & Medicaid Services (CMS) confirms the nearly 4.5 percent cut to surgeons and anesthesiologists, harming patient access to needed surgical care, the Surgical Care Coalition said today. 

Key Points: 
  • "Without Congressional action, vulnerable seniors' nationwide access to timely, high quality, and essential surgical care will be negatively impacted.
  • Combined with a 4% Medicare cut stemming from the Statutory Pay-As-You-Go Act, surgical care will face a nearly 8.5% Medicare cut on January 1, 2023.
  • Meanwhile, significant medical inflation, along with staffing and supply chain shortages, continues to harm surgical care teams across the country.
  • The Surgical Care Coalition advocates for access to quality surgical care for all Americans.